Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study
Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid...
Saved in:
| Published in | BMC cancer Vol. 22; no. 1; pp. 1 - 1043 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central Ltd
05.10.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Keywords: Rectal cancer, Liquid chromatography-mass spectrometry, Safe margin, Metabolites |
|---|---|
| AbstractList | Abstract Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography–mass spectrometry (LC–MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Keywords: Rectal cancer, Liquid chromatography-mass spectrometry, Safe margin, Metabolites Abstract Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography–mass spectrometry (LC–MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. BACKGROUNDRectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. METHODSA total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography-mass spectrometry (LC-MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. RESULTSWe found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. CONCLUSIONSThere are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive technique for the study of cancers. Methods A total of 150 tissue samples from 25 rectal cancer patients were analyzed by liquid chromatography–mass spectrometry (LC–MS), and 6 tissue samples were collected from each patient (group 1: tumor; group 2: 0.5 cm from tumor; group 3:1 cm from tumor; group 4:2 cm from tumor; group 5:3 cm from tumor and group 6:5 cm from tumor). The differential metabolites of tumor tissues and 5 cm from the tumor (normal tissues) were first selected. The differential metabolites between tumor tissues and normal tissues were regrouped by hierarchical clustering analysis, and further selected by discriminant analysis according to the regrouping of clustering results. The potential safe margin of clinical T(cT)1,cT2 stage rectal cancer and cT3,cT4 stage rectal cancer at the metabolomic level was further identified by observing the changes in the level of differential metabolites within the samples from group 1 to group 6. Results We found 22 specific metabolites to distinguish tumor tissue and normal tissue. The most significant changes in metabolite levels were observed at 0.5 cm (cT1, cT2) and 2.0 cm (cT3, cT4) from the tumor, while the changes in the tissues afterwards showed a stable trend. Conclusions There are differential metabolites between tumor tissues and normal tissues in rectal cancer. Based on our limited sample size, the safe distal incision margin for rectal cancer surgery in metabolites may be 0.5 cm in patients with cT1 and cT2 stage rectal cancer and 2.0 cm in patients with cT3 and cT4 stage rectal cancer. |
| ArticleNumber | 1043 |
| Audience | Academic |
| Author | Zhang, Shaopeng Wang, Daguang Pan, Guoqiang Liu, Zhifeng Kong, Yuan |
| Author_xml | – sequence: 1 givenname: Shaopeng surname: Zhang fullname: Zhang, Shaopeng – sequence: 2 givenname: Guoqiang surname: Pan fullname: Pan, Guoqiang – sequence: 3 givenname: Zhifeng surname: Liu fullname: Liu, Zhifeng – sequence: 4 givenname: Yuan surname: Kong fullname: Kong, Yuan – sequence: 5 givenname: Daguang surname: Wang fullname: Wang, Daguang |
| BookMark | eNptkl1rFDEUhgepYFv9A14NCKIXU5PMR7JeCEvxY6Eg-HEdziQnM1myk5pkWvvvze5W7YgEksPJc94kJ-9ZcTL5CYviOSUXlIruTaRMiLYijFWUUNZU7FFxShtOK9YQfvIgflKcxbglhHJBxGkxrmP0ykKyfiq9KR3eoIv7aIcJeu9swlje2jSWacQygsFyB2GwBzqgSuBKBZPCUMY5DBju3pbwu9jvrIplTLO-e1o8NuAiPrtfz4vvH95_u_xUXX3-uLlcX1WqbbtUKSNAkM40qDVowntGueEMOgqiJ0LUjdBCaNMymuem6VUPplasw94Q4Lo-LzZHXe1hK6-Dzbe9kx6sPCR8GCSEZJVDmVU0aXlNVG2aVSNWYBRBFH1vmk5zkrXeHbWu536HWuGUAriF6HJnsqMc_I1ctXXd1jwLvLoXCP7HjDHJnY0KnYMJ_Rwl44zVlK66NqMv_kG3fg5TbtWe6ginvO3-UgPkB9jJ-Hyu2ovKNWeUMk6oyNTFf6g8NOYPyc4xNucXBa8XBZlJ-DMNMMcoN1-_LNmXD9gRwaUxejfvHRSXIDuCKvgYA5o_jaNE7l0rj66V2bXy4FrJ6l9hXOC3 |
| Cites_doi | 10.1016/j.ebiom.2019.10.005 10.1007/s00595-020-01959-y 10.1515/raon-2016-0030 10.1159/000274464 10.4174/astr.2015.89.1.23 10.1097/DCR.0b013e318233fc4a 10.1038/cgt.2016.52 10.1002/jcla.23333 10.1038/s41416-018-0357-6 10.1002/bjs.11478 10.1007/s00384-016-2708-1 10.1002/jcp.26850 10.1245/s10434-008-0125-6 10.1097/DCR.0000000000000900 10.2174/0929867323666160818093854 10.18632/oncotarget.16727 10.1111/codi.12608 10.1016/j.ejca.2018.07.005 10.3389/fonc.2017.00325 10.1038/s41575-020-0275-y 10.4103/0973-1482.175428 10.1016/j.ijsu.2019.07.029 10.1007/DCR.0b013e3181f052d4 10.1007/978-1-4939-9027-6_15 10.3393/ac.2013.29.6.231 10.1073/pnas.1408129111 10.1111/cyt.12484 10.1002/ijc.32843 10.1097/00000478-200203000-00009 10.1007/978-3-319-47656-8_9 10.1038/s41419-018-0313-7 10.1016/j.canep.2019.02.003 10.1007/s00216-015-8662-x 10.1158/1055-9965.EPI-14-0980 10.1038/s41598-021-02438-1 10.1245/s10434-011-2035-2 10.1002/jcp.25287 10.1016/j.cgh.2007.03.016 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
| Copyright_xml | – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
| DBID | AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-022-10124-2 |
| DatabaseName | CrossRef Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 1043 |
| ExternalDocumentID | oai_doaj_org_article_df5d05730c3f49489afc0ee8bbf46d70 A721127018 10_1186_s12885_022_10124_2 |
| GeographicLocations | China Germany |
| GeographicLocations_xml | – name: China – name: Germany |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AFGXO ABVAZ AFNRJ 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c556t-cf8a806f4eddad07b217f72a61a8b088348d88df5218df44bcbaf3c26ebf0a7d3 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 22 15:05:29 EDT 2024 Tue Sep 17 21:30:29 EDT 2024 Fri Oct 25 00:49:48 EDT 2024 Thu Oct 10 19:12:58 EDT 2024 Fri Feb 23 00:08:57 EST 2024 Fri Feb 02 04:13:02 EST 2024 Thu Aug 01 19:24:47 EDT 2024 Tue Aug 20 22:13:48 EDT 2024 Thu Sep 12 17:02:36 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c556t-cf8a806f4eddad07b217f72a61a8b088348d88df5218df44bcbaf3c26ebf0a7d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533537/ |
| PQID | 2726071756 |
| PQPubID | 44074 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_df5d05730c3f49489afc0ee8bbf46d70 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9533537 proquest_miscellaneous_2722311965 proquest_journals_2726071756 gale_infotracmisc_A721127018 gale_infotracacademiconefile_A721127018 gale_incontextgauss_ISR_A721127018 gale_healthsolutions_A721127018 crossref_primary_10_1186_s12885_022_10124_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-05 |
| PublicationDateYYYYMMDD | 2022-10-05 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMC cancer |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | S Hasanpour-Heidari (10124_CR1) 2019; 59 L Jamali (10124_CR11) 2018; 233 JW Han (10124_CR28) 2013; 29 S Banerjee (10124_CR20) 2019; 1928 A Rutkowski (10124_CR22) 2008; 15 National Comprehensive Cancer Network (10124_CR24) 2020 MD Williams (10124_CR34) 2015; 407 FM Smith (10124_CR32) 2014; 16 E Faghihloo (10124_CR14) 2016; 23 GM Nash (10124_CR10) 2010; 53 E Virgilio (10124_CR3) 2018; 29 SH Song (10124_CR25) 2021; 11 J Grosek (10124_CR27) 2017; 51 DW Kang (10124_CR30) 2017; 32 MAB Melone (10124_CR39) 2018; 9 P Manegold (10124_CR26) 2019; 69 WG Zeng (10124_CR29) 2017; 60 H Mirzaei (10124_CR15) 2016; 23 F Zhang (10124_CR4) 2017; 8 MJ Gosens (10124_CR9) 2007; 5 D Calligaris (10124_CR17) 2014; 111 K Vijayalakshmi (10124_CR18) 2020; 147 J Ferlay (10124_CR2) 2018; 103 VE Pricolo (10124_CR23) 2010; 27 ID Nagtegaal (10124_CR8) 2002; 26 K Bujko (10124_CR21) 2012; 19 P Sirniö (10124_CR37) 2019; 120 Y Shimada (10124_CR33) 2011; 54 A Han (10124_CR40) 2016; 231 KS Hong (10124_CR31) 2015; 89 MC Fernandes Messias (10124_CR35) 2017; 7 T Wiggins (10124_CR38) 2015; 24 XH Yang (10124_CR19) 2019; 48 AK Kaushik (10124_CR12) 2018; 1870 DS Keller (10124_CR6) 2020; 17 M Kosuge (10124_CR5) 2020; 50 EA Agger (10124_CR7) 2020; 107 M Simonian (10124_CR13) 2018; 14 EG Armitage (10124_CR16) 2017; 965 J Wu (10124_CR36) 2020; 34 |
| References_xml | – volume: 48 start-page: 81 year: 2019 ident: 10124_CR19 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.10.005 contributor: fullname: XH Yang – volume: 50 start-page: 743 issue: 7 year: 2020 ident: 10124_CR5 publication-title: Surg Today. doi: 10.1007/s00595-020-01959-y contributor: fullname: M Kosuge – volume: 51 start-page: 169 issue: 2 year: 2017 ident: 10124_CR27 publication-title: Radiol Oncol doi: 10.1515/raon-2016-0030 contributor: fullname: J Grosek – volume: 27 start-page: 185 issue: 3 year: 2010 ident: 10124_CR23 publication-title: Dig Surg doi: 10.1159/000274464 contributor: fullname: VE Pricolo – volume: 89 start-page: 23 issue: 1 year: 2015 ident: 10124_CR31 publication-title: Ann Surg treat Res doi: 10.4174/astr.2015.89.1.23 contributor: fullname: KS Hong – volume: 54 start-page: 1510 issue: 12 year: 2011 ident: 10124_CR33 publication-title: Dis Colon Rectum doi: 10.1097/DCR.0b013e318233fc4a contributor: fullname: Y Shimada – volume: 23 start-page: 396 issue: 11 year: 2016 ident: 10124_CR14 publication-title: Cancer Gene Ther doi: 10.1038/cgt.2016.52 contributor: fullname: E Faghihloo – volume: 34 issue: 8 year: 2020 ident: 10124_CR36 publication-title: J Clin Lab Anal doi: 10.1002/jcla.23333 contributor: fullname: J Wu – volume: 120 start-page: 238 issue: 2 year: 2019 ident: 10124_CR37 publication-title: Br J Cancer doi: 10.1038/s41416-018-0357-6 contributor: fullname: P Sirniö – volume: 107 start-page: 580 issue: 5 year: 2020 ident: 10124_CR7 publication-title: Br J Surg doi: 10.1002/bjs.11478 contributor: fullname: EA Agger – volume: 32 start-page: 325 issue: 3 year: 2017 ident: 10124_CR30 publication-title: Int J Colorectal Dis doi: 10.1007/s00384-016-2708-1 contributor: fullname: DW Kang – volume: 233 start-page: 8538 issue: 11 year: 2018 ident: 10124_CR11 publication-title: J Cell Physiol. doi: 10.1002/jcp.26850 contributor: fullname: L Jamali – volume: 15 start-page: 3124 issue: 11 year: 2008 ident: 10124_CR22 publication-title: Ann Surg Oncol doi: 10.1245/s10434-008-0125-6 contributor: fullname: A Rutkowski – volume: 60 start-page: 1175 issue: 11 year: 2017 ident: 10124_CR29 publication-title: Dis Colon Rectum doi: 10.1097/DCR.0000000000000900 contributor: fullname: WG Zeng – volume: 23 start-page: 4135 issue: 36 year: 2016 ident: 10124_CR15 publication-title: Curr Med Chem doi: 10.2174/0929867323666160818093854 contributor: fullname: H Mirzaei – volume: 8 start-page: 35460 issue: 21 year: 2017 ident: 10124_CR4 publication-title: Oncotarget doi: 10.18632/oncotarget.16727 contributor: fullname: F Zhang – volume: 16 start-page: 610 issue: 8 year: 2014 ident: 10124_CR32 publication-title: Colorectal Dis doi: 10.1111/codi.12608 contributor: fullname: FM Smith – volume: 103 start-page: 356 year: 2018 ident: 10124_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.07.005 contributor: fullname: J Ferlay – volume: 7 start-page: 325 year: 2017 ident: 10124_CR35 publication-title: Front Oncol doi: 10.3389/fonc.2017.00325 contributor: fullname: MC Fernandes Messias – volume: 17 start-page: 414 issue: 7 year: 2020 ident: 10124_CR6 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-020-0275-y contributor: fullname: DS Keller – volume: 1870 start-page: 2 issue: 1 year: 2018 ident: 10124_CR12 publication-title: Biochim Biophys Acta contributor: fullname: AK Kaushik – volume: 14 start-page: 475 issue: 2 year: 2018 ident: 10124_CR13 publication-title: J Cancer Res Ther doi: 10.4103/0973-1482.175428 contributor: fullname: M Simonian – volume: 69 start-page: 77 year: 2019 ident: 10124_CR26 publication-title: Int J Surg doi: 10.1016/j.ijsu.2019.07.029 contributor: fullname: P Manegold – volume: 53 start-page: 1365 issue: 10 year: 2010 ident: 10124_CR10 publication-title: Dis Colon Rectum doi: 10.1007/DCR.0b013e3181f052d4 contributor: fullname: GM Nash – volume: 1928 start-page: 275 year: 2019 ident: 10124_CR20 publication-title: Methods in molecular biology (Clifton, NJ) doi: 10.1007/978-1-4939-9027-6_15 contributor: fullname: S Banerjee – volume: 29 start-page: 231 issue: 6 year: 2013 ident: 10124_CR28 publication-title: Ann Coloproctol doi: 10.3393/ac.2013.29.6.231 contributor: fullname: JW Han – volume: 111 start-page: 15184 issue: 42 year: 2014 ident: 10124_CR17 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1408129111 contributor: fullname: D Calligaris – volume: 29 start-page: 41 issue: 1 year: 2018 ident: 10124_CR3 publication-title: Cytopathology doi: 10.1111/cyt.12484 contributor: fullname: E Virgilio – volume: 147 start-page: 256 issue: 1 year: 2020 ident: 10124_CR18 publication-title: Int J Cancer. doi: 10.1002/ijc.32843 contributor: fullname: K Vijayalakshmi – volume-title: NCCN Clinical Practice Guidelines in Oncology: Rectal cancer (version 2.2020) year: 2020 ident: 10124_CR24 contributor: fullname: National Comprehensive Cancer Network – volume: 26 start-page: 350 issue: 3 year: 2002 ident: 10124_CR8 publication-title: Am J Surg Pathol doi: 10.1097/00000478-200203000-00009 contributor: fullname: ID Nagtegaal – volume: 965 start-page: 209 year: 2017 ident: 10124_CR16 publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-47656-8_9 contributor: fullname: EG Armitage – volume: 9 start-page: 228 issue: 2 year: 2018 ident: 10124_CR39 publication-title: Cell Death Dis doi: 10.1038/s41419-018-0313-7 contributor: fullname: MAB Melone – volume: 59 start-page: 143 year: 2019 ident: 10124_CR1 publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2019.02.003 contributor: fullname: S Hasanpour-Heidari – volume: 407 start-page: 4581 issue: 16 year: 2015 ident: 10124_CR34 publication-title: Anal Bioanal Chem doi: 10.1007/s00216-015-8662-x contributor: fullname: MD Williams – volume: 24 start-page: 32 issue: 1 year: 2015 ident: 10124_CR38 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-14-0980 contributor: fullname: T Wiggins – volume: 11 start-page: 22943 issue: 1 year: 2021 ident: 10124_CR25 publication-title: Sci Rep doi: 10.1038/s41598-021-02438-1 contributor: fullname: SH Song – volume: 19 start-page: 801 issue: 3 year: 2012 ident: 10124_CR21 publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-2035-2 contributor: fullname: K Bujko – volume: 231 start-page: 1804 issue: 8 year: 2016 ident: 10124_CR40 publication-title: J Cell Physiol doi: 10.1002/jcp.25287 contributor: fullname: A Han – volume: 5 start-page: 997 issue: 8 year: 2007 ident: 10124_CR9 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2007.03.016 contributor: fullname: MJ Gosens |
| SSID | ssj0017808 |
| Score | 2.4067035 |
| Snippet | Abstract
Background
Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive... Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and... Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and non-destructive... BACKGROUNDRectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive and... Abstract Background Rectal cancer is one of the most lethal of gastrointestinal malignancies. Metabonomics has gradually developed as a convenient, inexpensive... |
| SourceID | doaj pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database |
| StartPage | 1 |
| SubjectTerms | Analysis Blood diseases Calibration Cancer Cancer surgery Care and treatment Chromatography Colorectal cancer Colorectal surgery Diagnosis Discriminant analysis Energy Ions Liquid chromatography Liquid chromatography–mass spectrometry Mass spectrometry Mass spectroscopy Metabolites Metabolomics Methods Patient outcomes Patients Rectal cancer Rectum Safe margin Scientific imaging Software Surgery Tumors |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBQxC4oCiep34sdwKoipIcAAq9Wb52VZqs2i9-_-ZsZPVBg5cuEXxJEq-Lx574pnPhLwRfbBOYtqgTrHtF7jNS2KxjdpHlyAe6ELJtvgmT8_6L-fifG-rL8wJq_LAFbijkERA0T7mu4RSJkubPItRO7iTDKpG62w5BVPj-oHSTE8lMloeZfDCGiuReYt6Vn3LZ8NQUev_2yf_mSe5N_Cc3CN3xxkjPa5Pep_cisMDcvvruCb-kFzuIUxXiV5jGlDGo5u4AYqxyDhT_N9KYbJHs02R3tj1xVWxRocHd_dI_prmWiT9ntrpYixazrSI0D4iZyeffn48bcf9E1ovhNy0PmmrmUx9DMEGphyEH0lxKxdWO_AuXa-D1gAwDPMBeHHe2dR5LoElZlXoHpODYTXEJ4R2HXeCRR0tcrBAkT2IxISP0nG3FH1D3k1wml9VJsOU8EJLU8E3AL4p4BvekA-I-M4SJa7LCSDejMSbfxHfkJfIl6n1oruOao4xpuWKLXRDXhcLlLkYMI_mwm5zNp9_fJ8ZvR2N0gpI9nYsS4D3RmWsmeXhzBL6oZ83Tx-OGf1ANlxxFPBTQjbk1a4Zr8TctiGutsUGJtmo7NgQNfvgZgDNW4ary6IFjtnBolNP_weiz8gdXrtIy8QhOdist_E5TLk27kXpXb8BCYEq0A priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA96BfFF_MS1VaMIPsjSXHbzUV-klZYqWKRa6FvI57Vgd-vl7v9vJps9uwq-LMtmstmdmUwyycwvCL1jrdOGQ9igDL5u53DMSyC-9tJ6E5I_0LgcbXHCj8_ar-fsvCy4xRJWOdrEbKhdb2GNfJcKClBogvFP179rODUKdlfLERp30RZNngKZoa2Dw5Pvp5t9BCGJHFNlJN-NyRpLyEimNeBatTWdDEcZtf9f2_x3vOStAejoIXpQZo54fxD1I3THd4_RvW9lb_wJurjFadwH_AvCgSLcXflVEjUkG0cM6644Tfpw1MHjK71cXGZqMHzp7RaUYInjkCz9EeuxMiQvR5zBaJ-is6PDn5-P63KOQm0Z46vaBqkl4aH1zmlHhEluSBBU87mWJlmZppVOShfSSJ6ubWus0aGxlCdpES1c8wzNur7zzxFuGmoY8dJrgJWZA9he8siY9dxQs8faCn0Y2amuB7gMld0MydXAfJWYrzLzFa3QAXB8QwlQ1_lBv1yo0nNU-i4HqI3ENgEa3dPBEu-lSarEnSAVeg3yUkPe6KbDqn3wbakgc1mht5kC4C46iKdZ6HWM6suP0wnR-0IU-iRkq0t6QvpvQMiaUO5MKFN_tNPiUXFUsQdR_dHeCr3ZFENNiHHrfL_ONGmyDQiPFRIThZswaFrSXV5kTHCIEmaNePH_xrfRfToof03YDpqtlmv_Mk2qVuZV6Tk3umoiwA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Na9VAEF9KBfEifmJq1VUEDxJNNpvdrSBSxVIFPagPelv287XQJm3yHuh_78wmeTbag5cQspOPnZ2Z3cnO_IaQ5zX3xgoMG1Qx5LzEMi-xCHlQLtgI_kDlU7TFV3G44J-P6qMtMpU7GhnYX-naYT2pRXf66ufFr3eg8G-TwivxugcbqzDPmOWIVsVzMMnXGAdPHUP5-J9dBalShboSDDLuKsgpiebKZ8wmqoTn_6_V_juS8tLUdHCL3BzXlHR_EILbZCs0d8j1L-Ou-V1yfGkMaBvpKQYK9Xh2FlYgBJiG3FP8I0thOUh7EwM9M93yJFGjSYSnOxSPjvZDGvUbaqabMa25pwmm9h5ZHHz88eEwHyss5K6uxSp3URlViMiD98YX0oKDEiUzojTKgv2puPJK-QhzPBw5t86aWDkmYBwLI311n2w3bRMeEFpVzNZFUMEg4EyJMHzgq9UuCMvsXs0z8nJipz4fgDR0ckCU0APzNTBfJ-ZrlpH3yPENJYJgpwttt9SjTmn4Lo94joWrIr50z0RXhKAsCJnwssjIExwvPWSUblRZ76PXy2RRqow8SxQIhNFgpM3SrPtef_r-bUb0YiSKLQyyM2PiAvQbsbNmlLszStBUN2-eBEdPgq6ZZAjxJ2uRkaebZrwTo9-a0K4TDSzDEfsxI3ImcDMGzVuak-OEFo7xw3Uld_6nqw_JDTaoQF7Uu2R71a3DI1h0rezjpEm_AeXXKFo priority: 102 providerName: Scholars Portal |
| Title | Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study |
| URI | https://www.proquest.com/docview/2726071756 https://search.proquest.com/docview/2722311965 https://pubmed.ncbi.nlm.nih.gov/PMC9533537 https://doaj.org/article/df5d05730c3f49489afc0ee8bbf46d70 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2Mvo_ti3tpMG4M9DDeObH10b01p6QYpJVsh7EVIspQGGqfEyf-_O9kO9fa2FxGsk-3c6U46-3c_E_KZF6WxAmGDKvi0GOFnXkLmU6-ctwHygbyMaItrcXVb_Jjx2R7hXS1MBO07uzip7pcn1eIuYisflm7Y4cSGN5NzhETyXA73yT5M0C5Fb18dSJWprjpGiWENAVhhETJLkcqqSFlvBYpE_f-G478hko_WnMtD8rzdLNKz5qZekD1fvSRPJ-3r8Ffk7pFy6SrQe0QA1fhr6TdgXawvrik-aqWwz6O1CZ4uzXq-iNIY6-DsDu2-pnVTH_2Nmm4w1ivXNPLPvia3lxe_zq_S9tMJqeNcbFIXlFGZCIUvS1Nm0kLmESQzYmSUhcCSF6pUqgyweENbFNZZE3LHBBgoM7LM35CDalX5t4TmObM888obZJIZIb8eJGHceWGZPeVFQr526tQPDUOGjpmFErpRvgbl66h8zRIyRo3vJJHdOh5Yree6tbGG-yqRqDFzecCLnprgMu-VhdkjSpkl5APaSzelojsf1WeYzjKZjVRCPkUJZLioEEIzN9u61t9_TntCX1qhsAIjO9NWJMD_RlKsnuRRTxJc0PW7u4mj2xBQayYZcvdJLhLycdeNIxHWVvnVNsrA_hpJHRMiexOup6B-D3hFpAFvveDdf498T56xxi_SjB-Rg816649hi7WxA3CsmRyQJ-OL65vpID6ogHZSKGin49-D6HJ_AOcGLgo |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8VQDhRqExAFFdZzEdrmggqi20PYArbQ3y89tJZqU9e7_x-M4SwMSlyiKJ8nuvOxxZr5B6G3bWKUZpA0K78qmgjYvnrjSCeO0j_FAbVO2xSmbnTdf5-08b7iFnFY5-sTkqG1vYI98j3IKUGi8ZR-vf5XQNQq-ruYWGrfRHcDhgg4GfL4JuCouiBgLZQTbC9EXC6hHpiWgWjUlnUxGCbP_X8_8d7bkjenn8CF6kNeN-GAQ9CN0y3WP0d2T_GX8Cbq4wWfce_wTkoECnF25VRQ0lBoHDLuuOC75cFDe4Su1XFwmanB78ekGVGCJw1Aq_QGr8WYoXQ44QdE-ReeHX84-z8rcRaE0bctWpfFCCcJ846xVlnAdgxDPqWKVEjr6mLoRVgjr4zwej02jjVa-NpRFWRHFbf0MbXV957YRjizWLXHCKQCVqQBqL8ZjrXFMU73fNgV6P7JTXg9gGTIFGYLJgfkyMl8m5ktaoE_A8Q0lAF2nC_1yIbPdyPi7LGA2ElN7eOm-8oY4J3RUJGY5KdAuyEsOVaMbc5UHENlSTipRoDeJAsAuOsimWah1CPLox_cJ0btM5PsoZKNycUL834CPNaHcmVBGazTT4VFxZPYGQf7R3QK93gzDnZDh1rl-nWjiUhvwHQvEJwo3YdB0pLu8SIjgkCPc1vz5_1--i-7Nzk6O5fHR6bcX6D4dDKEk7Q7aWi3X7mVcXq30q2RDvwGy_iRL |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgSBMXfqNlG8wgJA4oreskjsdtDKoN2DQBkyYuln9uE2taNe2Fv573nKRqxm2XqqqfW8fv84tf873PhLwrcqeNQNqgDD7NR3jMS2A-9dJ6EyAfyFxkW5yKo_P860VxsXbUVyTtW3M9qG4mg-r6KnIrZxM77Hhiw7OTQ6REFlk5nLkwvE8ewJplokvU2wcIpWSyq5GRYlhDGJZYisxTFLTKU967D0W5_v-D8m2i5NqdZ_yY_O7G3BBO_gyWCzOwf2_JOd7pop6QR-1-lB40Jk_JPV89I5sn7RP35-RqzX90GugNkoxqfDfxCwAQljDXFP_NpbCVpLUOnk70HMaGNhhO4dstQmtO66YE-yPVXWcsia5plLh9Qc7HX34dHqXt6QypLQqxSG2QGuY95N457VhpILkJJddipKWB2JXl0knpAuwP4DXPjTU6ZJYLwADTpcteko1qWvktQrOMm4J56TWK1YxQwg_yvMJ6YbjZL_KEfOh8pWaNCIeKyYsUqvGsAs-q6FnFE_IJ3bmyRAHt-MF0fqnaGVcwLodakMxmAX90XwfLvJcGACpcyRKyh2BQTTXqKgyoA8yYeclGMiFvowWKaFTI0rnUy7pWxz9_9Izet0ZhCgiyui16gOtG3a2e5W7PEla57Td3qFRtlKkVLznKA5aFSMibVTP2ROZc5afLaANbeNSNTEjZQ3NvgvotgNGoNN5icvvOPffI5tnnsfp-fPpthzzkzfpLWbFLNhbzpX8FG7qFeR2X7j-5Jk0k |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+levels+of+metabolites+with+the+safe+margin+of+rectal+cancer+surgery%3A+a+metabolomics+study&rft.jtitle=BMC+cancer&rft.au=Zhang%2C+Shaopeng&rft.au=Pan%2C+Guoqiang&rft.au=Liu%2C+Zhifeng&rft.au=Kong%2C+Yuan&rft.date=2022-10-05&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-022-10124-2&rft.externalDBID=ISR&rft.externalDocID=A721127018 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |